CIK 0001689375 · Accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813983399
- Phone
- 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-03 | Dowden Nathan J President & COO | Shares withheld for taxes | −5,144 | $11.68 | $60K | 180,805 |
| 2025-03-03 | Sethuraman Natarajan President, Research & Develop. | Shares withheld for taxes | −6,138 | $11.68 | $72K | 199,659 |
| 2025-03-01 | Doshi Dipal CEO | Grant or award | +116,200 | 441,953 | ||
| 2025-03-01 | Doshi Dipal CEO | Grant or award · Stock Option (Right to Buy) | +173,400 | 173,400 | ||
| 2025-03-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award | +42,400 | 116,249 | ||
| 2025-03-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +63,300 | 63,300 | ||
| 2025-03-01 | Dowden Nathan J President & COO | Grant or award | +60,800 | 185,949 | ||
| 2025-03-01 | Dowden Nathan J President & COO | Grant or award · Stock Option (Right to Buy) | +90,800 | 90,800 | ||
| 2025-03-01 | Sethuraman Natarajan President, Research & Develop. | Grant or award | +60,800 | 205,797 | ||
| 2025-03-01 | Sethuraman Natarajan President, Research & Develop. | Grant or award · Stock Option (Right to Buy) | +90,800 | 90,800 | ||
| 2024-12-11 | MPM BIOVENTURES 2018, L.P. 10% owner | Sale | −21,787 | $20.23 | $441K | 4,381,062 |
| 2024-12-11 | MPM BioVentures 2014, L.P. 10% owner | Sale | −21,787 | $20.23 | $441K | 4,381,062 |
| 2024-12-10 | MPM BIOVENTURES 2018, L.P. 10% owner | Sale | −22,935 | $20.77 | $476K | 4,402,849 |
| 2024-12-10 | MPM BioVentures 2014, L.P. 10% owner | Sale | −22,935 | $20.77 | $476K | 4,402,849 |
| 2024-12-03 | Sethuraman Natarajan President, Research & Develop. | Sale 10b5-1 | −11,703 | $20.15 | $236K | 144,997 |
| 2024-12-02 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise 10b5-1 | +5,000 | $2.10 | $11K | 78,849 |
| 2024-12-02 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −5,000 | $20.00 | $100K | 73,849 |
| 2024-12-02 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 31,157 | ||
| 2024-12-02 | Sethuraman Natarajan President, Research & Develop. | Sale 10b5-1 | −4,088 | $20.26 | $83K | 156,700 |
| 2024-11-29 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise 10b5-1 | +1,000 | $2.10 | $2K | 74,849 |
Page 7 of 12 · 230 trades